Related Experiment Video
Updated: Sep 17, 2025

Mouse In Vivo Placental Targeted CRISPR Manipulation
Published on: April 14, 2023
miR-381-3p contribution in mouse spontaneous abortion via targeting VEGFA
Chao Ding1, Fukang Liu1, Huayue Shi1
1School of Traditional Chinese Medicine & School of Traditional Chinese, Nanjing University of Chinese Medicine, Nanjing, Jiangsu, China.
Background:
Recurrent spontaneous abortion (RSA) affects 1-5% of pregnant women; however, the mechanisms underlying this condition remain unknown. Dysangiogenesis in the placenta is an essential factor in the pathogenesis of RSA. Studies have verified that microRNAs (miRNAs) are vital for RSA; however, their mechanism of action in regulating angiogenesis remains unclear. Therefore, we explored the contribution of key miRNAs that regulate angiogenesis in RSA.
Methods:
The abortion mouse model was constructed by intraperitoneal injection of beta2-Glycoprotein I (β2-GPI). The abnormal expression of miRNAs in the placenta of the abortion mice was screened using miRNA-seq. Based on miRNA databases, miR-381-3p, which is highly expressed in abortion mice, may bind to vascular endothelial growth factor A (VEGFA). Subsequently, we investigated the effects of the miR-381-3p/VEGFA axis on the angiogenesis of vascular endothelial cells using real-time quantitative polymerase chain reaction, Transwell, wound healing, tube formation, western blotting, and dual-luciferase reporter system. Furthermore, an in vivo experiment was used to confirm miR-381-3p knockdown contribution in the abortion mouse model.
Results:
miR-381-3p overexpression inhibited the migration and angiogenesis of C166 cells (a mouse vascular endothelial cell line), whereas miR-381-3p knockdown had the opposite effect. The dual-luciferase reporter system revealed that miR-381-3p bound to the VEGFA 3' UTR, and VEGFA knockdown counteracted the beneficial effect of the miR-381-3p inhibitor on angiogenesis. An in vivo study demonstrated that miR-381-3p knockdown may reduce inflammation and damage to the placenta and fetus during abortion by activating the VEGFA/nuclear factor kappa B (NF-κB) pathway.
Conclusion:
miR-381-3p may cause insufficient placental blood flow by inhibiting the VEGFA pathway and can be used as a potential therapeutic target for RSA.

